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Abstract: This work demonstrated for the first time the synthesis of novel chlorhexidine 
particles containing strontium and zinc, to provide an effective, affordable, and safe 
intervention in the treatment of recurrent infections found in Medicine and Dentistry. The 
CHX-SrCl2 and CHX-ZnCl2 particles were synthesized by co-precipitation of chlorhexidine 
diacetate (CHXD) and zinc chloride or strontium chloride, where particle size was 
manipulated by controlling processing time and temperature. The CHX-ZnCl2 and CHX-
SrCl2 particles were characterized using SEM, FTIR, and XRD. UV-Vis using artificial 
saliva (pH 4 and pH 7) was used to measure the drug release and ICP-OES ion release. 
The antibacterial properties were examined against P. gingivalis, A. 
actinomycetemcomitans., and F. nucleatum subsp. Polymorphum, and cytotoxicity was 
evaluated using mouse fibroblast L929 cells. The novel particles were as safe as 
commercial CHXD, with antibacterial activity against a range of oral pathogens. UV-Vis 
results run in artificial saliva (pH 4 and pH 7) indicated a higher release rate in acidic rather 
than neutral conditions. The CHX-ZnCl2 particles provided the functionality of a smart Zinc 
and CHX release, with respect to environmental pH, allowing responsive antibacterial 
applications in the field of medicine and dentistry. 
 









Antiseptics are widely applied for preventing and reducing wound and surgical infections, 
which continue to be a major problem in health care [1]. This can be particularly difficult to 
manage in developing countries due to lack of resources, high costs, and special storage 
conditions of antibacterial agents [2]. Lack of suitable antibacterial agents can however 
lead to high infection rates and even death [3], due to ventilator associated pneumonia and 
sepsis [4]. An effective, affordable, and safe intervention for preventing infections and 
improving public health is therefore in high demand. 
Chlorhexidine (CHX) is an antibacterial agent [5–7] widely applied in medicine and 
dentistry [8,9]. It has been used for daily bathing of critically ill patients in intensive care 
units [10] or as a neonatal wipe for cord care [11]. In the dental field, it is used to control 
dental plaque [12] and reduce surgical/recurrent infections (e.g., periodontal disease and 
endodontic disease) [13–16]. As a broadspectrum antibacterial agent, CHX provides both 
bactericidal and bacteriostatic effects by producing nonspecific binding to the negatively 
charged membrane phospholipids of the bacteria. This leads to alteration in bacterial 
osmotic equilibrium. When the CHX concentration is increased the cytoplasm contents 
precipitate, causing cell death [17,18]. 
Many systems have been proposed for chlorhexidine delivery, where the direct addition of 
chlorhexidine gluconate solution (4%) [19] is used for burns and wounds, or 0.12–0.3% 
CHX in a mouthwash as common methods of reducing bacterial load [20,21]. Generally, 
the incorporation of CHX gluconate into loading systems involves gels and varnishes. 
Biodegradable chips or incorporation into polymers are also feasible methods [22,23]. The 
low drug loading capacity, burst drug release, and strong binding formed between the drug 
and the polymeric matrix, however, limits its antibacterial efficacy [24,25]. To achieve 
effective chlorhexidine delivery, modification of the chlorhexidine formulation is one of the 
promising and feasible strategies. Previous studies suggested the co-precipitation of 
CHXD with CaCl2 to produce CHX-CaCl2 spheres, which demonstrated sustained release 
behavior and high CHX content (95%) [26]. It is also possible to substitute Ca2+ ions within 
the structure with other ions, to bring additional therapeutic benefits. Good candidates for 
this particle substitution are ions such as Zn2+ and Sr2+ to optimize antimicrobial activity 
[27–29]. 
The presence of strontium (Sr) would be beneficial to perform the dual action of bone 
stimulation and bone resorption suppression [30,31]. Numerous studies demonstrate 
strontium is able to promote pre-osteoblast proliferation, osteoblast differentiation, bone 
matrix mineralization, and stimulate type I collagen protein levels [32], while inhibiting 
osteoclast differentiation [33]. Therefore, strontium inclusion would be particularly useful in 
the treatment of implant and surgical associated infections (peri-implantitis) found in 
dentistry. Strontium has also been shown to significantly enhance the remineralizing effect 
of fluoride ion (F−) [34] and to help remineralize dentine in vitro [35]. 
Zinc (Zn) has various positive characteristics, such as angiogenic, osteogenic, and 
antimicrobial properties [36]. Zn2+ is attracted to the negatively charged microbe cell 
membrane, penetrates it, and reacts with sulfhydryl within it. Thus, the activity of 
synthetase in the microbe is damaged and the cells lose the ability of mitosis, which leads 
to death of the microbe [37]. In practice, owing to its bacteriostatic properties, zinc is in-
corporated in dental filling materials, mouth rinses, and toothpastes [38]. The release rate 
of Zn increases dramatically under acidic conditions in Zn containing silicate glasses, 
enabling Zn release during bacterial infections at low pH value (pH = 4.5) [39]. This 
particular property would also be very attractive in the development of a smart release 
antiseptic. 
Therefore, the aim of the work is to use low-cost reagents and energy-saving synthesis to 
develop a novel drug delivery particle that can pH responsively release anti-bacterial 
agents of CHX and metal ions to take advantage of their therapeutic functions, thus 
providing a safe and effective antimicrobial environment for dental and medical 
applications. 
2. Materials and Methods 
2.1. Materials 
Chlorhexidine diacetate (C6143, Lot: 4G013891), strontium chloride hexahydrate (204463, 
Lot MKC131848V); zinc chloride (229997; Lot MKCC2307), KH2PO4 (P3786, Lot 
#BCBC2041), Hepes (lot SLBW8459), KCL (Lot BCBZ4557), and phosphate-buffered 
saline (PBS, Lot 1762519) were all purchased from Sigma-Aldrich (Gillingham, Dorset, UK). 
All the solutions were prepared using deionized (DI) water (Milli-Q, Millipore Co., Bedford, 
MA, USA) with an 18.2 MΩ·cm resistance. 
2.2. Chlorhexidine particle synthesis 
The chlorhexidine (CHX) particles were synthesized by coprecipitation of 15 mg/mL 
chlorhexidine diacetate (CHXD) with 0.33 M of SrCl2 or ZnCl2, mixed at 1:1 by volume at 
room temperature. The mixtures were left for 1 min and then centrifuged at 2400 rpm for 1 
min (Eppendorf centrifuge 5417C, Germany). After wash with 1 mL deionized water, the 
precipitates were placed into liquid nitrogen for 30 min, and then transferred to a freeze 
dryer (ScanVac Cool Safe Freeze Drying, Denmark) at −107 °C, 0.009 mBar for 24 h. Both 
strontium (CHX-SrCl2) and zinc containing particles (CHX-ZnCl2) were synthesized 
following the same procedures. The synthesized particles were then stored at 4 °C and 
wrapped in aluminum foil paper to exclude the light, ready for further characterization. 
To evaluate the influence of temperature on CHX-SrCl2 and CHX-ZnCl2 particle formation, 
both CHXD and SrCl2/ZnCl2 solutions were kept in a temperature-controlled water bath or 
ice bath (IKA RET basic C, UK) at selected temperature points of 0, 5, 10, 15, 20, and 
25 °C. The coprecipitation process was then carried out at these selected temperatures 
using the same procedures and storage as previously. 
To demonstrate the influence of the reaction times on the formation of both particles, 20 μL 
CHXD solution (15 mg/mL) was added onto glass slides and left for one minute, 20 μL 
SrCl2 or ZnCl2 (0.33 M) was further added and reacted for 15 s, 30 s, 45 s, and 60 s. Then 
the excess liquid was carefully removed with fuzz-free lab wipes. Statistical differences 
between particle diameter for each test group (reaction time or temperature) were 
determined using a one-way Anova test (p < 0.05, SPSS Inc., Chicago, IL, USA). 
2.3. UV-Vis Spectrometer 
For CHX concentration determination, a series of CHXD standard solutions (1, 3, 5, 10, 20, 
30, and 50 ppm) were prepared and measured using UV–Vis spectrometry (Lambda 35, 
Perkin Elmer, USA). The measured data were used to obtain a linear calibration curve 
between the absorbance intensity (at 254 nm) and the CHX concentration. 
The release kinetics of the particles were tested by weighing 0.01 g of CHX-SrCl2 or CHX-
ZnCl2 particles into 2 ml centrifuge tubes containing 2 ml phosphate buffered saline. At 
specified time points (Table S1), the samples were centrifuged, and the supernatant was 
collected for UV−Vis spectrometry measurements. Fresh PBS (2 ml) was then replaced, 
and the procedure repeated at the next time points. Cumulative release curves were 
formed by further calculation of the CHX release at each time point. The yield of CHX was 
calculated using the overall amount of CHX in the original solutions subtracted from the 
amount of CHX left in the synthesis supernatant and washing solutions. 
The release behavior of the CHX-ZnCl2 particles was also tested in artificial saliva (AS) of 
pH 4 and pH 7. First, 0.04 g of CHX-ZnCl2 particles were placed into 15 mL centrifuge 
tubes (Eppendorf, Germany), containing 8 ml AS (pH = 4 or pH = 7) and the solutions were 
replaced as per the previous timetable. At each time point samples were centrifuged, and 
the supernatants were measured using UV-Vis spectrometry to gather the CHX 
concentration and to calculate the cumulative CHX release. 
2.4. Inductively Coupled Plasma-Optical Emission Spectroscopy 
Elemental calibration standards were prepared from pure element standards (1000 ppm 
standards in deionized water, VWR), which were diluted in deionized water to produce 0, 
1, 5, 10, 50, and 100 ppm concentrations of each ion. The zinc content of the calibration 
standards was measured using inductively coupled plasma-optical emission spectroscopy 
(ICP-OES; Varian Vista-PRO, Yarnton, UK). 
ICP-OSE was employed for measuring the zinc release curve of CHX-ZnCl2 particles in 
AS of pH = 4 and pH = 7, according to the time points in Table S1 (up to 7 h). At each time 
point, samples were centrifuged, and the supernatants were collected and replaced with 
fresh AS. All the experiments were repeated in triplicate. 
2.5. Structural Analysis of the CHX-SrCl2 and CHX-ZnCl2 Particles 
The morphology of CHX-SrCl2, CHX-ZnCl2 particles, and prepared tissue samples were 
evaluated using scanning electron microscopy (SEM, FEI inspect-F, Hillsboro, USA), after 
gold coating using a sputter coating system (SC 7620, Quorum, Laughton, UK), for 45 s at 
20 mA. Samples were analyzed at 10 kV, with a spot size of 3.0. SEM photomicrographs 
were taken to assess the different morphology, and size distribution of the CHX-SrCl2 and 
CHX-ZnCl2 particles at selected temperatures and different reaction times. 
 
Elemental analysis of the CHX-SrCl2 and CHX-ZnCl2 particles was conducted using 
Energy Dispersive Spectroscopy (EDS, FEI Inspect F, NanoPort, Eindhoven, The Neth-
erlands). X-ray diffraction (XRD) was employed using an X’Pert Pro X-ray Diffractometer 
(Panalytical, Almelo, The Netherlands) to characterize the structural information of CHXD 
and novel CHX particles. Fourier Transform Infrared Spectroscopy (FTIR, Bruker, Billerica, 
MA) was further applied to analyze the chemical structures of the CHX-SrCl2 and CHX-
ZnCl2 particles. 
2.6. Antimicrobial Assay 
Porphyromonas gingivalis (strain-381), Fusobacterium nucleatum subspecies nucleatum 
(strain-ATCC10953), and Aggregatibacter actinomycetemcomitans (strain-Y4) were used 
to test the antibacterial activity of CHXD, CHX-SrCl2, and CHX-ZnCl2 particles. Bacteria 
were grown on blood agar plates (Blood Agar Base No.2; Oxford, UK) and 5% defibrinated 
horse blood (TCS, UK) in an anaerobic atmosphere (10% H2, 10% CO2, and 80% N2), at 
37 °C for 48 h. The resulting colonies were inoculated and suspended into 20 mL brain 
heart infusion broth (BHI) (CM1135; Oxford, UK), supplemented with 0.5 μg/mL Vitamin K 
and 0.5 μg/mL hemin. The bacterial culture was then grown for 24 h anaerobically. Bacterial 
numbers in the BHI broth were determined and standardized by serial dilution and 
measured for colony forming units (CFUs) on blood agar plates. After overnight incubation 
in an anaerobic environment, the bacterial suspensions were diluted (1:20) in pure BHI, to 
achieve an optical density of 0.1 for Porphyromonas gingivalis and Aggregatibacter 
actinomycetemcomitans, and 0.2 for Fusobacterium nucleatum at 600 nm (OD600). This 
gave approximately 6.36 × 107 colony-forming units (CFU) per ml, to standardize the 
bacterial inoculum used in these experiments. 
The MIC (minimum inhibitory concentration) is the lowest or minimum antimicrobial 
concentration that inhibits visible microbial growth in artificial media after a fixed incubation 
time. This was determined by placing a known quantity of bacteria in 96 well plates, and 
then adding a series of dilutions ranging from 0.0000625–0.004% of CHXD powder, CHX-
SrCl2, or CHX-ZnCl2 particles in sterile deionized water. The test wells were a) bacterial 
suspensions with 225 μL BHI and 25 μL of CHXD, CHX-SrCl2, or CHX-ZnCl2 particle 
dilutions (0.0000625–0.004%); Controls with: b) 225 μL BHI and 25 μL sterile water; c) 
bacterial suspension with 225 μL BHI; d) bacterial suspension with 225 μL BHI and 25 μL 
of sterile water. All experiments had six duplicate wells and three independent experiments. 
The plates were incubated for 24 h in an anaerobic incubator and OD was measured at 
595 nm (OD595 nm), to calculate the bacterial growth. After incubation the MBC was 
confirmed by transferring the microliter well contents to microcentrifuge tubes, then 
centrifuging the bacterial suspension solution (5 min). The bacteria were washed to remove 
any remaining CHX-SrCl2, CHX-ZnCl2, particles or CHXD, then re-suspended on blood 
agar plates. After 24–72 h incubation, bactericidal activity was confirmed by observation of 
any bacterial colonies on the culture plate. When 99.9% of the bacterial population was 
killed at the concentration of the CHXD or novel CHX particles, it was termed the MBC 
(minimum bactericidal concentration). This was done by observing pre- and post-incubated 
agar plates for the presence or absence of bacteria. 
2.7. Cytotoxicity Assay 
Cytotoxicity of the CHX particles was evaluated with a standard 3-(4,5 dimethyl-thiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay with the L929 cell line (ECACC, 
85011425). The MTT activity reflects mitochondrial activity, which can indicate viable cells. 
The cell viability of CHX-SrCl2, CHX-ZnCl2, and CHXD particles were tested using three 
independent experiments each, with six replicate wells for all antimicrobial agent 
concentrations tested. Cells were cultured in Dulbecco’s modified eagle’s medium (DMEM, 
Lonza, Switzerland), supplemented with 10% fetal bovine serum (FBS), 100 μg/mL 
penicillin, and 100 μg/mL streptomycin. This was carried out in a humidified incubator 
atmosphere (5% CO2 at 37 °C), then seeded in 96-well microliter plates at 10,000 cells 
per well. The cell was incubated overnight, after that the medium was removed, and cells 
were washed by PBS twice. CHX-SrCl2, CHX-ZnCl2, and CHXD particles were separately 
dissolved in sterilized DI water, then diluted in cell culture media to get the concentrations 
from 0.0000625 to 0.004%. The treatment solutions were used to treat cells for 24 and 48 
h. After this, treatments were removed, and 50 μL of 5 mg/mL tetrazolium salt MTT was 
added into each well and then incubated at 37 °C for 4 h. The medium was next removed, 
and MTT was solubilized in 100 μL isopropanol in each well. The absorbance of the solution 
was measured with a plate reader at 570 nm. 
For each test, results were expressed as mean (SD)%. The original optical density of the 
examination culture was calculated as a percentage of the control medium optical density. 
It is assumed that the absorption value of the control group represents 100% viability. 
Statistical differences between the Zn or Sr containing particles and CHXD within 
concentration groups were determined using independent t-tests (SPSS Inc., Chicago, IL, 
USA). 
To demonstrate the influence of novel CHX particle synthesis on tissue adherence, three 
tissue sections (10 mm length × 6 mm depth) were removed from the lingual wall of a lower 
jaw of a pig’s head, at 2 mm from the gingival margins, using a scalpel (Swann Morton, 
Sheffield UK). The tissue sections were mounted onto metal SEM stubs using copper tape. 
Human saliva (20 mL) was collected from underneath the tongue and placed in a 30 mL 
universal container (Star lab, UK) and stored at 37 °C in an incubator. A micro-brush 
(Stewmac #3101, UK) was dipped into a dappens pot containing 1 mL of human saliva and 
it was then applied to the surface of all the tissue mounted samples. 
One tissue section was used as a control group without any particle coating. The other two 
tissue sections were coated with CHX-ZnCl2 and CHX-SrCl2 particles respectively. CHX 
particles were synthesized onto the surface of the moisturized tissue sections and also on 
a separate SEM stub (Figure S7), by the co-precipitation of 10μL CHXD solution (15 mg/mL) 
and 10μL of 0.33 mol/L of either ZnCl2 or SrCl2 solutions. Then, the solution was then 
removed by syringing with 2 ml human saliva drop by drop within 4 min. 
3. Results and Discussion 
3.1. Synthesis and Characterization of CHX-SrCl2 and CHX-ZnCl2 Particles 
CHXD and chlorhexidine di-gluconate are the common components of antibacterial drugs 
that have been extensively applied in the field of medicine and dentistry [40,41]. The 
authors previously proposed a novel method for preparation of spherical CHX-CaCl2 
particles, using CHXD to coordinate with CaCl2 [26]. The incorporated calcium ions, 
however, may hold less significant antibacterial and therapeutic functions. In the present 
work, a novel method of producing functionalized spherical CHX particles is demonstrated 
by substituting zinc and strontium ions into the particle structure to enhance antibacterial 
effects. Strontium and zinc ions are both divalent metal ions with ionic radii (Sr = 1.16 Å, 
Zn = 0.74 Å) close to calcium (0.94 Å) [42,43] facilitating this substitution. The substitution 
of calcium by strontium and zinc has become a feasible route, especially in the application 
of bioactive glasses [44,45]. 
The CHX-SrCl2 and CHX-ZnCl2 particles were evaluated using scanning electron 
microscopy (SEM) with the results shown in Figure 1. Generally, both CHX-SrCl2 and CHX-
ZnCl2 particles demonstrated unique spherical morphologies of a porous and in-
terconnected dendritic structure, grown from a nucleation site central to the sphere (Figure 
1a,b). This was in contrast to the angular shaped solid morphology of original CHXD 
platelet (Figure 1c). The mean (SD) diameters of the prepared CHX particles (synthesized 
at 25 °C) were: 17.5 (4.39) μm (CHX-SrCl2) and 14.2 (4.71) μm (CHX-ZnCl2), which were 
significantly smaller than original CHXD crystals of 80 (30) μm. 
 
Figure 1. SEM images of (a) CHX-SrCl2 particles; (b) CHX-ZnCl2 particles; (c) CHX 
diacetate particles. 
The EDS results of the CHX-SrCl2 particles (Figure 2a–c) indicated an even distribution of 
strontium and chloride throughout the particle and associated with its structure. Similarly, 
Figure 2d–f demonstrated a homogeneous distribution of zinc and chloride ions in the 
CHX-ZnCl2 particles. Quantitative elemental analysis indicated that the weight percentage 
of divalent ions incorporated in the CHX particles was 3.95 wt% and 7.66 wt% for strontium 
and zinc, respectively (Figures S1 and S2, Tables S2 and S3). Additionally, it is noteworthy 
to mention that the CHX-SrCl2 and CHX-ZnCl2 particles were washed with DI water to 
remove unreacted elements and any physically absorbed divalent metal ions. The zinc and 
strontium ions were therefore confirmed evenly incorporated into particle structures. 
 
Figure 2. (a) SEM photomicrograph of CHX-SrCl2 particle; (b) EDS mapping of chloride in 
CHX-SrCl2 particle; (c) EDS mapping of strontium; (d) SEM photomicrograph of CHX-
ZnCl2 particle; (e) EDS mapping of chloride in CHX-ZnCl2 particle; (f) EDS mapping of zinc. 
The FTIR results of the CHX-SrCl2, CHX-ZnCl2, and CHXD particles are shown in Figure 
3. In the infrared spectrum of the CHXD, there are three absorption peaks at 3325 cm−1, 
3120 cm−1, and 3180 cm−1, which may be attributed to the stretching vibrations N-H of 
the groups (Alkyl)2 NH, Alkyl-NH-Aryl, and to the group =NH, respectively [46]. A typical 
band at 1612 cm−1 can also be assigned to the stretching vibration of the imine group C=N 
[47,48]. The IR spectrum of the CHX-SrCl2 and CHX-ZnCl2 particles for the band of the 
imine group displays a positive shift from 1612 cm−1 to 1623 cm−1. In addition, after 
forming the novel CHX particles, the stretching vibrations N–H of the groups (Alkyl)2 NH 
and the group =NH showed significant shifts as well. Based on the comparisons between 
the infrared spectrums of the CHX-SrCl2, CHX-ZnCl2 particles, and CHXD, it is inferred 
that the electron density was affected and changed the position of –C=NH in favor of the 
addition of metal ions. Coordination might therefore be formed between the biguanides of 
the novel CHX particles and the divalent metal ions through the formation of four metal–N 
bonds with two bidentate ligands in the square-planar structure [49,50]. A similar 
phenomenon of chelated chlorhexidine complexes has been previously found and the 
mechanisms discussed [28,29,51]. EDS analysis of CHX-SrCl2 and CHX-ZnCl2 particles 
also confirms the structural presence and homogeneous distribution of the metal cations 
and chloride. It can be assumed that the coordination of chlorhexidine to the divalent metal 
(Zn, Sr) ions happened during particle formation. Consequently, both the negatively 
charged chloride ions and the counterpart divalent metal ions are responsible for the 
formation of novel chlorhexidine particles. EDS revealed a higher ratio (25.4–28.3 at%) of 
Cl− ions compared to cations distributed within the particles (Tables S2 and S3). The 
additional chloride ions may reduce the solubility of the chlorhexidine as well as influence 
the rate of structural formation, whilst the metal ions may contribute to the production of 
the compactness of spherical microstructure as previously proposed [26]. 
 
Figure 3. FTIR results of CHX-SrCl2, CHX-ZnCl2, and CHXD particles. 
The XRD plots of the CHX-SrCl2 and CHX-ZnCl2 particles indicated they had missing 
peaks at the 6.20, 11.40, 14.47, 16.18, 16.61, 19.09, and 36.27 degree 2 theta positions, 
which were present in the CHXD XRD plot. There were also slight deviations in the 2 theta 
positions, changes in intensity for similar peaks for the CHXD and the novel particles, and 
signs of peak broadening (Figure 4). Crystal lattice strain and crystal size can affect XRD 
peak broadening, the intensity of the peaks and shifts in 2 theta positions [52]. XRD peak 
broadening has been previously associated with smaller crystallite size and changes to the 
lattice parameters, due to zinc incorporation into hydroxyapatite structure [53]. The CHX-
SrCl2 and CHX-ZnCl2 particles also displayed new peak positions (not in the CHXD plot) 
at 15.81, 15.85, 18.55, 20.02, 20.83, 21.56, 28.85, 28.88, 29.85, 29.88, 31.22, 35.43, and 
35.46 degrees 2 theta. The CHX-SrCl2 and CHX-ZnCl2 particles displayed almost the 
same 2 theta positions, indicating the formation of a similar particle structure after the 
incorporation of divalent metal ions (Sr, Zn). It is clear the new particle complexes displayed 
structural differences with CHXD which were confirmed by differences in polymorph 
structure and crystallite size (Figure 1). 
 
Figure 4. The X-ray diffraction results for CHX-SrCl2, CHX-ZnCl2, and CHXD particles. 
3.2. Influence of Reaction Time and Temperature on Particle Size 
Reaction time and temperature are factors that can affect the crystallization processes. 
The crystallization reaction of the CHXD and SrCl2/ZnCl2 solutions appeared to be 
extremely rapid (turbidity in 0.05 secs, Figure S3), with a statistical increase in mean 
particle diameter (p < 0.05) with increased reaction time (Figure 5a–c). Both particles 
showed dendritic and spherical structures and statistical differences in mean particle 
diameter between all reaction time groups (p < 0.05). The CHX-SrCl2 and CHX-ZnCl2 
particles were also produced at selected temperature points (0 °C to 25 °C), and the results 
are shown in Figure S4. There was a statistical increase in mean particle diameter with 
increase in synthesis temperature for both particles (Figure S4a–c). Both particles showed 
statistical differences in mean particle diameter between all selected temperature groups 
(p < 0.05). This is due to the essential role that temperature plays in the nucleation and 
crystal growth process [26]. Specifically, increased temperature will not only encourage the 
movement of ions, thereby speeding up the rate of crystal growth, but also decrease 
nucleation centers and increase the critical size of the nucleus, resulting in the formation 
of particles of larger size [54,55]. At lower temperatures, both the molecular movement and 
the critical nucleus size will be reduced, which may facilitate molecules binding and 
attaching impurities in their structure, forming a large number of smaller crystals [56]. This 
may partially explain the results in Figure S4a–c, as at 0 °C the novel particles exhibited 
the formation and agglomeration of smaller crystallites, whereas crystal growth increased 
in response to higher temperatures. 
Crystallization of the current CHX-SrCl2 and CHX-ZnCl2 particles required a limited 
reaction time and energy input to produce spherical particles. This reactive crystallization 
may in part be due to the differing pH of the solutions used (pH 7.42 for CHXD-15 mg/mL, 
pH 5.03 for SrCl2 and pH 5.31 for ZnCl2), producing formation of a lower solubility solute 
with higher concentration and allowing crystallization [56]. These pH differences are 
significant since the pH scale is a logarithmic and therefore a 1 pH unit increase leads to 
tenfold increases in H+ concentration. Jiang et al. 2005 [57] indicated the particle size of 
SnO2 nanoparticles via colloids could similarly be controlled from 6 to 12 nm by varying 
pH value from 2 to 6. This co-precipitation process requires much higher nucleation and 
growth times/temperatures and mechanical agitation [58], to control particle size and 
distribution [56]. The present work provides a simple method to control particle size/surface 
area, so structure property particle relations can be tailored for applications, such as electro 
spinning, coating, or incorporation in microcontainers for drug delivery [59,60]. 
 
Figure 5. SEM images of (a) CHX-ZnCl2 particles; (b) CHX-SrCl2 particles at different 
reaction times; and (c) plots showing the correlation between the mean particle diameter 
and reaction time for both CHX-SrCl2 and CHX-ZnCl2 particles. 
3.3. Antibacterial and Cytotoxicity Assay 
For an antimicrobial agent to be efficacious in the treatment of a disease, it must be 
effective against the involved pathogens. The antimicrobial tests showed that the 
concentration of both CHX-SrCl2 and CHX-ZnCl2 particles required to inhibit (MIC) 
planktonic P. gingivalis (strain-381) and A. actinomycetemcomitans (strain-Y4) was 
0.00025% at both 24 and 48-h time points, demonstrating their antibacterial efficacy in 
comparison to the CHXD (Figure S5). The concentration of CHX particles required to inhibit 
(MIC) planktonic F. nucleatum subsp. polymorphum (strain- ATCC10953) was 0.0005% at 
24 and 48-h time points (Figure S5), again consistent with the efficacy of the commercial 
CHXD comparison antimicrobial. 
The MBC results are shown in Table 1 (P. gingivalis and A. actinomycetemcomitans) and 
Table 2 (F. nucleatum subsp. polymorphum). The MIC and MBC of CHX-SrCl2 and CHX-
ZnCl2 particles against P. gingivalis, A. actinomycetemcomitans and F. nucleatum subsp. 
Polymorphum were consistent with CHXD and in the range of 0.0000625–0.004%. The 
confirmation of MIC/MBC of CHX-SrCl2 and CHX-ZnCl2 particles against the bacteria 
tested provided an effective concentration range when conducting release experiments. 
The efficacy of chlorhexidine as an antibacterial drug is proven; however, tissue exposed 
to high CHX concentrations (>0.5–2%) [61] for long periods, may have adverse effects on 
the oral tissues [62,63]. The potential cytotoxic effects and safe concentration levels of the 
novel particles were, therefore, evaluated. There were significant differences (p < 0.05) 
between the novel particles and CHXD at 0.0005% at 24 h, and the concentrations from 
0.0000625% to 0.0005% at 48 h (Figure 6a,b). 
 




SrCl2, CHX-ZnCl2 or CHXD 
24 h 48 h 
0.00025% MIC MBC 
0.0005% MBC MBC 





SrCl2, CHX-ZnCl2, or 
CHXD 
24 h 48 h 
0.0005% MIC MIC 
0.001% MBC MBC 
0.002% MBC MBC 
 
Figure 6. Effects of CHXD, CHX-SrCl2, and CHX-ZnCl2 on the relative viability of fibroblast 
(L929) cells at (a) 24 h and (b) 48 h. Values shown are mean (SD) for triplicate cultures. * 
p < 0.05 = significant difference within groups vs. CHXD. 
Application of the CHXD, CHX-SrCl2, and CHX-ZnCl2 particles reduced the viability of the 
L929 cells in a dose-dependent manner, but to different degrees (Figure 6). Relative 
cellular viability was reduced to approximately 40% when 0.001% of CHX-SrCl2 and CHX-
ZnCl2 particles were used for 24 h, which was further decreased to around 2% after 48 h 
treatment. 
Similar results were reported for human gingival fibroblast cells indicating decreased cell 
proliferation and division when exposed to 0.01%-0.02% CHX for 15 min [64]. When 
evaluating the cell structure of the fibroblast cells exposed to the current CHXD solutions 
(>0.01%), the cells’ shape became more rounded and less prolific (Figure S6). 
Characteristic fibroblast spindle shaped morphology was previously shown to lack filopodia 
and present a more oval or rounded shape at 0.002–0.04% CHX concentration, indicating 
a significant influence of CHX concentration on cellular viability and morphology [64–66]. 
Lower concentrations of CHX-SrCl2 and CHX-ZnCl2 particles ranging from 0.0000625% to 
0.00025% showed approximately 90% and 60% cellular viability at 24 and 48 h, 
respectively. Although 0.0005% CHX-SrCl2 and CHX-ZnCl2 particles demonstrated above 
80% cellular viability at 24 h, this was reduced to around 40% at 48 h. Similar viability was 
observed in CHXD treated cultures. Interestingly, a CHX concentration of 0.00025% 
caused no reported apoptosis and necrosis in L929 fibroblasts [65], and no necrosis at 
0.125% CHX [65]. Current commercial products contain 0.12%–0.3% [20,21] CHX for 
mouthwashes and up to 4% for burns [67,68] which could significantly reduce cell viability. 
Furthermore, 0.05% CHX was reported as nontoxic to wound healing and granulation 
tissue [19], with no suggested bioaccumulation after repeated exposure at higher CHX 
levels [69]. Therefore, the current CHX-SrCl2, CHX-ZnCl2 particles have the potential as 
safe and effective antimicrobials. Synthesis of these particles in conjunction with moist 
pig’s tissue illustrates these particles do not bind to moist tissue, making local CHX 
absorption less likely (Figure S7). 
3.4. Release Kinetics of CHX Particles 
The CHX-SrCl2 and CHX-ZnCl2 particles both showed a rapid CHX release in the first day, 
followed by a sustained release until the end of the assay as shown in Figure 7. The 
sustained CHX release behavior was associated with the unique interconnected structure 
of the novel CHX particles whose dissolution process initiates from the particle interior [70]. 
 
Figure 7. Cumulative CHX release curves for CHX-SrCl2 and CHX-ZnCl2 particles in PBS. 
Arrows with red round or blue triangle represent the last time point of the release CHX 
concentration higher than MIC. 
To inhibit bacterial growth, a sufficient dosage for an effective duration is required locally 
at the infection site to prevent secondary infections [70]. When the CHX concentration in 
the infection area is, however, too high, both tissue cells and bacteria can be eliminated 
[25]. CHX digluconate mouth rinses (0.12–0.2%) indicate a substantivity <12 h, requiring 
multiple daily applications to be effective [71]. The CHX-SrCl2 offered an effective 
sustained release up to 8 days, as the CHX concentration of released solution was below 
MIC (<2.5 ppm) after 8 days. The CHX-ZnCl2 showed a similar sustained release pattern 
(above MIC) up till day 12 (2.96 ppm). This may be particularly beneficial in prevention of 
recurrent infections and maintenance of oral hygiene. The novel particles offer an effective 
CHX release up to 8 days for CHX-SrCl2 and 12 days for CHX-ZnCl2 particles, which may 
be particularly beneficial in prevention of recurrent infections and maintenance of oral 
hygiene. Sustained release delivery systems also allow a better antibacterial efficacy 
against bacteria [25,72]. The calculated chlorhexidine content in the CHX-SrCl2 and CHX-
ZnCl2 particles was around 98.6 wt% and 99.1 wt%, respectively, which was higher than 
many reported carriers [73]. Moreover, the CHX-SrCl2 or CHX-ZnCl2 particles were able 
to release additional antibacterial ions. CHX-SrCl2 particles contain strontium (Table S3) 
potentially available for release as an antibacterial agent, with the effects enhanced by the 
presence of fluoride [74]. Further work is however needed to assess any effects on bone 
regeneration at this Sr concentration present. 
The CHX-ZnCl2 particles had a higher CHX and Zn release rate in artificial saliva (pH 4), 
when compared to pH 7 (Figures 8 and S8). After 7 h, the overall zinc released was 140 
ppm for acidic artificial saliva (pH = 4), which was double that for neutral pH = 7 saliva (73 
ppm). Figure 8 indicates a lower sustained CHX release pattern in a pH 7 environment, 
whilst for pH 4, a higher and responsive CHX release in the initial stages. However, after 
the initial CHX responsive release in AS (pH 4), an effective antibacterial concentration 
could be maintained for 5 days. After 40 days the cumulative CHX release reached 3888 
ppm (AS = pH 7) versus 281 ppm for AS (pH 4). 
 
Figure 8. Cumulative zinc release from CHX-ZnCl2 particles in artificial saliva (pH = 4 or 
pH = 7). 
The study of the release kinetics of the CHX particle in an acidic environment is of great 
importance, because caries or tissue inflammation are present in an acidic environment 
[75]. Specifically, during the caries and tissue inflammation process, there is a pH reduction 
due to activity of mutans streptococci and lactobacilli [76], which triggers the local 
acidification processes, encouraging acidtolerant pathogenic bacteria to colonize [77]. The 
responsive and increased CHX release made available by the novel CHX-ZnCl2 particles 
is useful in this situation, particularly against drug resistant biofilms associated with 
surgical/recurrent infections [78]. In acidic condition (pH 4), the CHX can be rapidly 
released, providing an initial high dose of antibacterial drug, followed by a sustained and 
effective CHX release up to 5 days. This should be sufficient to arrest bacterial infections 
and maintain oral hygiene. In addition, if there were no potential infections (pH 7 
environment) CHX would be released in a sustained manner for 19 days (at MBC level) 
maintaining oral hygiene, but available for smart release to eliminate any earlystage 
infections. 
An acid environment may favor the dissolution of chlorhexidine [79], as it consists of two 
ionizable guanidine moieties [80] that demonstrate alkalinity [81]. The enhanced release 
rate of CHX will therefore also affect the zinc release behavior due to its dissolution. 
Furthermore, when AS (pH 7) contacted the surface of the hydrophilic CHX-ZnCl2 particles, 
zinc ions were released, due to the high surface area of the unique porous and 
interconnected particle structure. When the AS was acidic (pH 4), the release rate of zinc 
ions was accelerated, suggesting that coordination bonds in the CHX-ZnCl2 particle 
deteriorated more rapidly in the acidic environment [82], thus encouraging the release of 
Zn2+ from the lattice of the CHX-ZnCl2 particle. The drug release of the novel CHX-ZnCl2 
particles can therefore vary with the surrounding pH values, enabling a responsive and 
controlled release of CHX and Zn. This is useful in the treatment of patients who are 
susceptible to bacterial infections, so early-stage disease effects are arrested or reversed. 
In particular, a reduction in oral bacterial load in COVID-19 patients may prevent 
pneumonia and acute respiratory distress syndrome, which can exacerbate patient 
morbidity [83]. It is noteworthy to mention that CHX-SrCl2 and CHX-ZnCl2 particles may 
have multiple applications including antibacterial mouth rinses, gels, cements, or coatings 
to take advantage of the sustained/smart release, or possible additional functions such as 
promoting bone proliferation [84]. The authors have incorporated novel CHX particles into 
injectable commercial gels for sustained drug delivery applications in a next step. This is 
expected to achieve long term sustained CHX release and antimicrobial efficacy, which is 
useful in the prevention of surgical and periodontal infections. 
4. Conclusions 
The current antibacterial CHX-SrCl2 and CHX-ZnCl2 formulations provide a cost effective 
and efficient drug synthesis route, whose size could be manipulated by adjusting synthesis 
time and temperature. They were effective against a range of oral pathogens with reduced 
cytotoxicity, extended duration, and with a smart pH responsive drug/ion release for the 
CHX-ZnCl2 particles. These particles show great potential for a new responsive treatment 
modality for the prevention or reversal of carries and infections in medicine and dentistry. 
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